Related Experiment Video
Updated: May 16, 2025
Studying Effects of Cigarette Smoke on Pseudomonas Infection in Lung Epithelial Cells
Published on: May 11, 2020
A global perspective on smoking's impact on peptic ulcer disease: DALY trends and projections
Chang Li1, Kun Jiang1, Shennan Pan1
1Department of Medical Laboratory, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, Jiangsu, China.
Objective:
This study aims to analyze global trends in smoking-attributable peptic ulcer disease (PUD) disability-adjusted life years (DALYs) from 1990 to 2021 and project future trends to 2046.
Methods:
Data were obtained from the Global Burden of Disease Study 2021. We calculated age-standardized DALYs rates (ASDR) and estimated annual percentage changes (EAPC) for smoking-attributable PUD DALYs. Bayesian Age-Period-Cohort models were used to project future trends.
Results:
From 1990 to 2021, global smoking-attributable PUD DALYs decreased significantly, with the age-standardized rate declining from 35.4 to 9.4 per 100,000 (EAPC: -4.45%). High-income regions showed faster declines, while some low- and middle-income countries experienced slower progress or even increases. Gender disparities were observed, with males consistently showing higher ASDR. Projections suggest a continued global decline in smoking-attributable PUD DALYs to 2046, with persistent regional disparities. By 2046, the global ASDR is expected to decrease to approximately 3.2 per 100,000, with higher rates persisting in certain regions such as Kiribati (44.6 per 100,000) and Cambodia (45.1 per 100,000).
Conclusion:
While global smoking-attributable PUD DALYs have significantly decreased and are projected to continue declining, substantial regional and gender disparities persist. These findings underscore the need for targeted tobacco control interventions, particularly in high-risk regions and among vulnerable populations, to further reduce the global burden of smoking-attributable PUD.
More Related Videos
Related Concept Videos
01:30Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:25Peptic Ulcer Disease V: Surgical Management and Nursing Care
Surgical Interventions for Peptic Ulcer Disease